HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Benzodiazepine
Benzodiazepine
The GABA-A (gamma-aminobutyric acid-A) benzodiazepine receptor in the central nervous system is affected by the class of medications known as benzodiazepines. Sedatives and antidepressants both include it. Benzodiazepines bind to the GABAnergic receptors in the brain, which lessens the sensitivity of the neurons to stimuli and has a calming effect. Uses of Benzodiazepines include
- Alcohol withdrawal
- Anxiety
- Panic Disorders
- As muscle relaxant
- Seizures
- Sleep disorder
- to induce relaxation and cause amnesia prior to surgical operations.
Committee Members
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain GAB 2025 Speakers
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Michelle Charbonnier
MoNetwork, United States
Monica Zuniga Fajuri
Tiburcio Vasquez Health Center, United StatesSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Gangstalking is real, should be studied
Sam Vaknin, Southern Federal University, United Kingdom
Title : Decoding aggression, violence, and substance use in adolescents with conduct disorders: Neurochemical pathways and interventions
Ann Marie Leonard Zabel, Curry College, United States
Title : Sensoria driven genetic decoupling and impaired areal integration in diseases of agency
Denis Larrivee, University of Navarra, Spain
Title : Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: A longitudinal study
Elizabeth Dale Gilley, The Elle Foundation, United States